Literature DB >> 3061819

Evaluation of the dose-effect relationship of a new ace inhibitor (perindopril) by an automatic blood pressure recorder.

R Luccioni1, Y Frances, R Gass, C Schwab, J P Santoni, L Perret.   

Abstract

Repeated blood pressure recordings by non-invasive devices are of better predictive value than single measurements in the evaluation of antihypertensive treatment. Such a method has been used to establish the dose-effect relationship of perindopril. After a two-week placebo run-in period, 40 patients with essential hypertension (age 56.6 +/- 1.5 years, 31 males, nine females) were treated with placebo or 2, 4 or 8 mg of perindopril once daily for one month following a randomized double-blind design. They were included if at least 75% of diastolic blood pressure recordings, made over an 8 h diurnal period using an automatic blood pressure recorder, were greater than 95 mmHg on placebo. Values (mean +/- SEM) before and after treatment were assessed using analysis of variance. These data showed a significantly greater reduction of blood pressure with 4 mg and 8 mg daily doses compared to placebo and the 2 mg daily dose. Such results were not obtained with blood pressure levels recorded by a mercury sphygmomanometer, confirming the value of an automatic blood pressure recorder as a tool in therapeutic trials.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3061819     DOI: 10.1093/oxfordjournals.eurheartj.a062410

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  7 in total

1.  The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects.

Authors:  C L Brown; C I Backhouse; J C Grippat; J P Santoni
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Perindopril. A review of its pharmacokinetics and clinical pharmacology.

Authors:  R J Macfadyen; K R Lees; J L Reid
Journal:  Drugs       Date:  1990       Impact factor: 9.546

3.  Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril.

Authors:  L Alcocer; C Campos; J H Bahena; A Nacaud; J Parra Carillo; C Calvo; C Weber; G Lerebours; L Mickalonis; M T Villahermosa
Journal:  Cardiovasc Drugs Ther       Date:  1995-06       Impact factor: 3.727

Review 4.  Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  P A Todd; A Fitton
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

5.  Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency.

Authors:  G A Verpooten; P M Genissel; J R Thomas; M E De Broe
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

Review 6.  Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.

Authors:  Balraj S Heran; Michelle My Wong; Inderjit K Heran; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

7.  Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol.

Authors:  Y K Seedat; I G Randeree
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.